AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “AVEO is a development-stage biopharmaceutical company focused on the development of cancer treatments. We are encouraged by the company’s progress with its lead pipeline candidate, tivozanib. Tivozanib is under review in the EU for the first-line treatment of renal cell carcinoma (RCC). Currently, the candidate is being evaluated in a couple of studies for the third-line treatment of RCC and advanced RCC. Meanwhile, AVEO is quite active on the partnering front. It has partnerships with Ophthotech and EUSA Pharma for tivozanib. Moreover, securing Novartis as a partner for cachexia candidate, AV-380, represents a huge positive for the company. Such deals provide the company with funds in the form of upfront and milestone payments. On the flip side, termination of the Pharmstandard agreement for tivozanib is concerning. Going forward, any hiccup on the development/regulatory front would impact its shares negatively.”
AVEO has been the topic of several other reports. FBR & Co reissued an “outperform” rating and issued a $3.00 price target on shares of AVEO Pharmaceuticals in a research note on Thursday, July 7th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Thursday, June 16th.
AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 0.8599 on Wednesday. The company’s market capitalization is $65.23 million. The stock’s 50 day moving average is $0.91 and its 200-day moving average is $0.95. AVEO Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.47.
A number of institutional investors have recently modified their holdings of AVEO. Spark Investment Management LLC purchased a new position in shares of AVEO Pharmaceuticals during the second quarter worth approximately $281,000. Bridgeway Capital Management Inc. increased its position in shares of AVEO Pharmaceuticals by 63.7% in the second quarter. Bridgeway Capital Management Inc. now owns 514,051 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 200,000 shares during the period. Renaissance Technologies LLC increased its position in shares of AVEO Pharmaceuticals by 6.0% in the first quarter. Renaissance Technologies LLC now owns 2,094,900 shares of the biopharmaceutical company’s stock worth $1,927,000 after buying an additional 119,000 shares during the period. Vanguard Group Inc. increased its position in shares of AVEO Pharmaceuticals by 1.1% in the second quarter. Vanguard Group Inc. now owns 2,470,485 shares of the biopharmaceutical company’s stock worth $2,374,000 after buying an additional 27,304 shares during the period. Finally, New Leaf Venture Partners L.L.C. bought a new stake in AVEO Pharmaceuticals during the second quarter worth about $2,490,000. 39.10% of the stock is currently owned by institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.